Inventor · disambiguated record
Andrew Carry Kruegel
Also filed as: KRUEGEL ANDREW · KRUEGEL ANDREW C · KRUEGEL ANDREW CARRY
14 granted patents·23 pending applications·40 citations·filing 2012–2024
89Inventor score
Top patents by PatentIndex Score
37 records- 0194US11440879B2Methods of treating mood disordersGILGAMESH PHARMACEUTICALS INC·Filed 2021·Granted Sep 13, 2022·6 cites·2 claims
- 0293US11912707B2Mitragynine alkaloids as opioid receptor modulatorsUNIV COLUMBIA·Filed 2021·Granted Feb 27, 2024·3 cites·11 claims
- 0391US10961244B2Mitragynine alkaloids as opioid receptor modulatorsUNIV COLUMBIA·Filed 2017·Granted Mar 30, 2021·6 cites·11 claims
- 0489US11760758B2Mitragynine analogs for the treatment of pain, mood disorders and substance use disordersUNIV COLUMBIA·Filed 2021·Granted Sep 19, 2023·6 cites·14 claims
- 0586US11344510B2Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disordersGILGAMESH PHARMACEUTICALS INC·Filed 2021·Granted May 31, 2022·1 cites·2 claims
- 0683US2024351983A1Methods of treating mood disordersGILGAMESH PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0782US2024317683A1Methods of treating mood disordersGILGAMESH PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0881US9988377B2Small molecule inducers of GDNF as potential new therapeutics for neuropsychiatric disordersSAMES DALIBOR·Filed 2012·Granted Jun 5, 2018·7 cites·26 claims
- 0980US10183919B2Class of mu-opioid receptor agonistsKRUEGEL ANDREW C·Filed 2015·Granted Jan 22, 2019·8 cites·37 claims
- 1080US2025122213A1Opioid receptor modulatorsUNIV COLUMBIA·Filed 2024·Application pending·0 cites
- 1179US12180158B1Crystalline fumarate salts of n-ethyl-2-(5-fluoro-1H-indol-3-yl)-n-methylethan-1-amineGILGAMESH PHARMACEUTICALS INC·Filed 2023·Granted Dec 31, 2024·0 cites·30 claims
- 1279US12157722B1Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amineGILGAMESH PHARMACEUTICALS INC·Filed 2023·Granted Dec 3, 2024·0 cites·10 claims
- 1377US12195478B2Opioid receptor modulatorsUNIV COLUMBIA·Filed 2023·Granted Jan 14, 2025·0 cites·18 claims
- 1476US2025115552A1Crystalline hydrochloride salts of n-ethyl-2-(5-fluoro-1h-indol-3-yl)-n-methylethan-1-amineGILGAMESH PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1572US2022241243A1Methods of treating mood disordersGILGAMESH PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1669US12129234B1Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amineGILGAMESH PHARMACEUTICALS INC·Filed 2023·Granted Oct 29, 2024·0 cites·30 claims
- 1769US11840541B2Opioid receptor modulatorsKRUEGEL ANDREW C·Filed 2015·Granted Dec 12, 2023·1 cites·27 claims
- 1869US11787772B2Carboxylic diarythiazepineamines as mixed mu- and delta-opioid receptor agonistsKRUEGEL ANDREW·Filed 2018·Granted Oct 17, 2023·1 cites·23 claims
- 1967US10844027B2Carboxylic diarylthiazepineamines as mu-opioid receptor agonistsKRUEGEL ANDREW·Filed 2016·Granted Nov 24, 2020·1 cites·21 claims
- 2064US2022409555A1Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disordersGILGAMESH PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2164US2022106279A1Class of mu-opioid receptor agonistsUNIV COLUMBIA·Filed 2021·Application pending·0 cites
- 2264US2025042851A1Crystalline salts of n-ethyl-(5-fluoro-1h-indol-3-yl)-n-methylethan-1-amineGILGAMESH PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2361US2025161264A1(ampar-pam)-nmda receptor antagonist combination therapy for treatment of mental conditions and disordersGILGAMESH PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2461US2025270173A1Pyridine derivatives for treating psychiatric disordersGILGAMESH PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2559US2024239798A1Salts and polymorphs of mitragynine and 3-deuteromitragynineKURES INC·Filed 2022·Application pending·0 cites
- 2658US2024390301A1Combinations of peripheral 5-ht2a receptor antagonists and central 5-ht2a receptor agonistsGILGAMESH PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2757US2023116703A1Novel ergolines and methods of treating mood disordersGILGAMESH PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2857US2024246911A1Novel tryptamines and methods of treating mood disordersGILGAMESH PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2956US2024368151A1Novel ergolines and methods of treating mood disordersGILGAMESH PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3055US2023365519A1Carboxylic diarylthiazepineamines and uses thereofKURES INC·Filed 2021·Application pending·0 cites
- 3155US2024092802A1Mu-opioid receptor agonists and uses thereforKURES INC·Filed 2021·Application pending·0 cites
- 3255US2024166618A1Phenalkylamines and methods of making and using the sameGILGAMESH PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3355US2023373940A1Carboxylic diarylthiazepineamines and uses thereofKURES INC·Filed 2021·Application pending·0 cites
- 3453US2023322735A1Azetidinyl tryptamines and methods of treating psychiatric disordersGILGAMESH PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3549US2019084949A1New class of mu-opioid receptor agonistsKRUEGEL ANDREW C·Filed 2018·Application pending·0 cites
- 3648US2024300886A1Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disordersGILGAMESH PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3748US2022135564A1Deuterated mitragynine analogs as safer opioid modulators in the mitragynine classUNIV COLUMBIA·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Andrew Carry Kruegel files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →